- Home
- TXN vs AMGN Comparison
TXN vs AMGN Comparison
Compare TXN & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXN
- AMGN
- Stock Information
- Founded
- TXN 1930
- AMGN 1980
- Country
- TXN United States
- AMGN United States
- Employees
- TXN N/A
- AMGN N/A
- Industry
- TXN Semiconductors
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TXN Technology
- AMGN Health Care
- Exchange
- TXN Nasdaq
- AMGN Nasdaq
- Market Cap
- TXN 137.4B
- AMGN 156.2B
- IPO Year
- TXN N/A
- AMGN N/A
- Fundamental
- Price
- TXN $188.08
- AMGN $289.57
- Analyst Decision
- TXN Hold
- AMGN Buy
- Analyst Count
- TXN 26
- AMGN 21
- Target Price
- TXN $192.50
- AMGN $323.62
- AVG Volume (30 Days)
- TXN 7.2M
- AMGN 3.0M
- Earning Date
- TXN 07-22-2025
- AMGN 05-01-2025
- Dividend Yield
- TXN 2.89%
- AMGN 3.29%
- EPS Growth
- TXN N/A
- AMGN 56.16
- EPS
- TXN 5.28
- AMGN 10.94
- Revenue
- TXN $16,049,000,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- TXN $11.94
- AMGN $7.73
- Revenue Next Year
- TXN $10.22
- AMGN $1.69
- P/E Ratio
- TXN $35.62
- AMGN $26.46
- Revenue Growth
- TXN N/A
- AMGN 15.56
- 52 Week Low
- TXN $139.95
- AMGN $253.30
- 52 Week High
- TXN $220.39
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- TXN 62.18
- AMGN 59.50
- Support Level
- TXN $179.76
- AMGN $269.10
- Resistance Level
- TXN $186.48
- AMGN $276.90
- Average True Range (ATR)
- TXN 4.12
- AMGN 5.54
- MACD
- TXN -0.17
- AMGN 2.81
- Stochastic Oscillator
- TXN 88.73
- AMGN 92.78
About TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.